What is the future outlook for CDK inhibitors in cancer therapy?
The future of CDK inhibitors in cancer therapy looks promising, with ongoing research aimed at improving their efficacy and minimizing side effects. Personalized medicine approaches, where CDK inhibitor treatment is tailored based on the genetic and molecular profile of the tumor, are likely to enhance patient outcomes. Additionally, the discovery of novel CDK targets and the development of multi-targeted inhibitors hold potential for advancing cancer treatment.
